Gilead Sciences, Inc.
Financial Advisor, March 2021
Agreement to Jointly Develop & Commercialize Long-acting, Investigational Combinations of Lenacapavir & Islatravir for the Treatment of HIV-1 with Merck
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK) today announced that they have entered into an agreement to co-develop and co-commercialize long-acting HIV-1 treatments that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people living with HIV-1.